PWMG
NKTR icon

Provence Wealth Management Group’s Nektar Therapeutics NKTR Stock Holding History

Provence Wealth Management Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23
Closed -$208 – 476
2023
Q3 		$208 Buy
+23
New +$221 ﹤0.01% 465

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Provence Wealth Management Group's NKTR Position: Q4 2023 in Review

Provence Wealth Management Group sold out of Nektar Therapeutics (NKTR) in Q4 2023, closing a stake of 23 shares — an estimated $208 sold.

Provence Wealth Management Group first reported a position in NKTR in Q3 2023 and held it in 1 quarter. The position peaked at $208 in Q3 2023. 125 funds tracked by Wall St. Rank hold NKTR as of Q4 2023.

  • Provence Wealth Management Group reported no remaining Nektar Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Provence Wealth Management Group sold 23 Nektar Therapeutics shares in Q4 2023, an estimated $208.
  • Provence Wealth Management Group first reported a position in Nektar Therapeutics in Q3 2023 and held it in 1 quarter.
  • Provence Wealth Management Group's Nektar Therapeutics position peaked at $208 in Q3 2023.
  • 125 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2023.

Based on Provence Wealth Management Group's 13F filing for Q4 2023, filed 6 Feb 2024.